Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ca-R-Pa-Diem in Newly Diagnosed Multiple Myeloma
NCT02802163Phase 2Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Jun 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of panobinostat in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Planned start Jun 2017; status: withdrawn.
02
Drugs
panobinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02802163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802163.